Anti-SARS-CoV-2 B and T-Cell Immune Responses Persist 12 Months After mRNA Vaccination with BNT162b2 in Systemic Lupus Erythematosus Patients Independently of Immunosuppressive Therapies DOI Creative Commons
Mario Ferraioli, Alessandra Aiello, I. Prevete

и другие.

Vaccines, Год журнала: 2025, Номер 13(4), С. 396 - 396

Опубликована: Апрель 9, 2025

Background: In response to the SARS-CoV-2 pandemic, a massive vaccination campaign was launched. Nonetheless, concerns arose regarding some peculiar groups of patients, including those affected by Systemic Lupus Erythematosus (SLE), because immune-suppressive drugs routinely administered patients and risk possible disease flares. Since effects third booster in SLE have been poorly assessed, this study aims evaluate immunogenicity safety BNT162b2 vaccine dose, together with immunosuppressive drugs. Methods: A monocentric cohort age- sex-matched healthy controls (HCs) (all vaccinated three homologous doses) were consecutively enrolled 6 months (T1) after their shot. Vaccine evaluated analyzing humoral cellular immune responses at T1 12 (T2). assessing adverse events related (T0) comparing activity among T0, T1, T2. Effects assessed stratifying according therapy vaccination: (1) receiving (IS) or (2) not (Non-IS). Results: At comparable between HC subjects, while significantly higher (p = 0.01). No differences found T2 cohorts. Similarly, both T2, IS Non-IS comparable. Moreover, lupus flares limited mostly mild, no life-threatening reported. Conclusions: The is safe induces an response, which persistent ongoing

Язык: Английский

Anti-SARS-CoV-2 B and T-Cell Immune Responses Persist 12 Months After mRNA Vaccination with BNT162b2 in Systemic Lupus Erythematosus Patients Independently of Immunosuppressive Therapies DOI Creative Commons
Mario Ferraioli, Alessandra Aiello, I. Prevete

и другие.

Vaccines, Год журнала: 2025, Номер 13(4), С. 396 - 396

Опубликована: Апрель 9, 2025

Background: In response to the SARS-CoV-2 pandemic, a massive vaccination campaign was launched. Nonetheless, concerns arose regarding some peculiar groups of patients, including those affected by Systemic Lupus Erythematosus (SLE), because immune-suppressive drugs routinely administered patients and risk possible disease flares. Since effects third booster in SLE have been poorly assessed, this study aims evaluate immunogenicity safety BNT162b2 vaccine dose, together with immunosuppressive drugs. Methods: A monocentric cohort age- sex-matched healthy controls (HCs) (all vaccinated three homologous doses) were consecutively enrolled 6 months (T1) after their shot. Vaccine evaluated analyzing humoral cellular immune responses at T1 12 (T2). assessing adverse events related (T0) comparing activity among T0, T1, T2. Effects assessed stratifying according therapy vaccination: (1) receiving (IS) or (2) not (Non-IS). Results: At comparable between HC subjects, while significantly higher (p = 0.01). No differences found T2 cohorts. Similarly, both T2, IS Non-IS comparable. Moreover, lupus flares limited mostly mild, no life-threatening reported. Conclusions: The is safe induces an response, which persistent ongoing

Язык: Английский

Процитировано

0